Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

LXEO

Lexeo Therapeutics Inc.

May 16 • 04:00PM ET

14.02

Dollar change +0.06
Percentage change 0.43	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWN IWO VTWO IWC RYLD VTWG VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.57	Insider Own	41.12%	Shs Outstand	26.65M	Perf Week	-3.31%
Market Cap	373.63M	Forward P/E	-	EPS next Y	-3.07	Insider Trans	-0.05%	Shs Float	15.69M	Perf Month	14.36%
Income	-69.42M	PEG	-	EPS next Q	-0.69	Inst Own	71.81%	Short Float	4.44%	Perf Quarter	-7.88%
Sales	0.00M	P/S	-	EPS this Y	77.25%	Inst Trans	-	Short Ratio	5.65	Perf Half Y	32.89%
Book/sh	5.56	P/B	2.52	EPS next Y	-8.87%	ROA	-47.71%	Short Interest	0.70M	Perf Year	-
Cash/sh	7.32	P/C	1.92	EPS next 5Y	-	ROE	-58.63%	52W Range	9.00 - 22.33	Perf YTD	4.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-36.24%	52W High	-37.21%	Beta	-
Dividend TTM	-	Quick Ratio	9.16	Sales past 5Y	19.69%	Gross Margin	-	52W Low	55.78%	ATR (14)	1.07
Dividend Ex-Date	-	Current Ratio	9.16	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	56.60	Volatility	8.31% 7.35%
Employees	58	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.00
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-10.67%	Payout	-	Rel Volume	2.72	Prev Close	13.96
Sales Surprise	-	EPS Surprise	-4.35%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	123.26K	Price	14.02
SMA20	8.75%	SMA50	1.92%	SMA200	-0.17%	Trades		Volume	335,730	Change	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-28-23	Initiated	Stifel	Buy	$20
Nov-28-23	Initiated	RBC Capital Mkts	Outperform	$22
Nov-28-23	Initiated	Leerink Partners	Outperform	$19
Nov-28-23	Initiated	JP Morgan	Overweight	$20
Nov-28-23	Initiated	Chardan Capital Markets	Buy	$23

May-14-24 12:00PM	What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet (Zacks)
May-09-24 07:00AM	Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire) +5.69%
May-07-24 07:30AM	Lexeo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-22-24 07:30AM	Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy (GlobeNewswire) +5.06%
07:30AM	Loading…
Apr-16-24 07:30AM	Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy (GlobeNewswire)
Mar-13-24 04:22PM	Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing (GlobeNewswire) +5.67%
Mar-11-24 07:42AM	Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)
07:30AM	Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing (GlobeNewswire)
Feb-05-24 07:00AM	Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments (GlobeNewswire)
Jan-03-24 07:00AM	Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 07:00AM	Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (GlobeNewswire) +8.71%
Dec-13-23 04:59AM	Lexeo Therapeutics Inc (LXEO) Reports Q3 2023 Financial Results and Advances Clinical Programs (GuruFocus.com)
Dec-11-23 12:05PM	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023 (InvestorPlace) -12.94%
07:00AM	Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
08:42AM	Loading…
Nov-30-23 08:42AM	J.P. Morgan Recommends These 2 Strong Buy Stocks With Over 60% Upside Potential (TipRanks)
Nov-02-23 09:51PM	Lexeo Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Townsend Richard Nolan	Chief Executive Officer	May 13 '24	Option Exercise	2.33	5,000	11,650	175,695	May 14 04:04 PM
Townsend Richard Nolan	Chief Executive Officer	May 13 '24	Sale	13.22	5,000	66,093	170,695	May 14 04:04 PM
Longitude Capital Partners IV,	10% Owner	Nov 07 '23	Buy	11.00	454,545	4,999,995	2,567,100	Nov 09 08:32 PM
Omega Fund VI, L.P.	10% Owner	Nov 07 '23	Buy	11.00	454,545	4,999,995	2,157,623	Nov 09 08:36 PM
Lundbeckfond Invest A/S	10% Owner	Nov 07 '23	Buy	11.00	227,272	2,499,992	1,835,959	Nov 09 08:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXEO

Lexeo Therapeutics Inc.

Upgrade your FINVIZ experience